Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Leukemia, Myeloid, Chronic-Phase 5 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Philadelphia Chromosome 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia 1 Gastrointestinal Stromal Tumors 1 GIST 1

Interventions

vandetanib 1 pazopanib 1 olverembatinib 1 lenvatinib 1 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × GIST × olverembatinib × Clear all

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡